Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Clinical trial NCT05098210 · RECRUITING

Trial details

NCT number: NCT05098210
Sponsor: Fred Hutchinson Cancer Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Anatomic Stage IV Breast Cancer AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Locally Advanced Cutaneous Melanoma Locally Advanced Mucosal Melanoma Metastatic Acral Melanoma Metastatic Conjunctival Melanoma Metastatic Cutaneous Melanoma Metastatic HER2-Negative Breast Carcinoma Metastatic Hormone Receptor-Positive Breast Carcinoma Metastatic Lung Non-Small Cell Carcinoma Metastatic Malignant Solid Neoplasm Metastatic Mucosal Melanoma

Start date: 2022-06-09
Primary completion: 2027-11-01
Enrollment: 28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.